In this issue:
Pembrolizumab for NSCLC patients with PS2
Atezolizumab plus chemotherapy with or without bevacizumab in NSCLC
Pembrolizumab plus etoposide and platinum for first-line extensive-stage SCLC
Pemetrexed plus cisplatin for completely resected nonsquamous NSCLC
Promoter DNA methylation and detection of NSCLC
Updated OS and PFS data from the ALEX study
Atezolizumab plus carboplatin and nab-paclitaxel in advanced squamous NSCLC
Brigatinib plus cetuximab for lung adenocarcinoma with T790M, and cis-C797S triple mutations
Selpercatinib in RET fusion-positive NSCLC
Molecular characterisation and clinical outcomes in RET-rearranged NSCLC
Tepotinib plus gefitinib in EGFR-mutant NSCLC and acquired resistance
Please login below to download this issue (PDF)